Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Part D Rebates and the Numbers Game: Pharma Readies for Post-Election Deficit Fight

This article was originally published in RPM Report

Executive Summary

PhRMA CEO Castellani readies for 2013 deficit reduction legislative debate by laying out how much money in the system is at stake.

You may also be interested in...

Part D Rebates: Talking Points Continue, But Deficit Deal Elusive

Once again the President is calling for rebates on prescription drugs sold under Medicare Part D. But without a big deficit deal involving entitlement reform, is there any way to enact them?

Merck CEO Frazier Stands Alone As Pharma Signatory Urging Fiscal Cliff Budget Deal

Coalition of business leaders that includes Merck CEO Ken Frazier pushes for deficit deal to avert sequestration. The reason seems simple: corporate tax reform.

The End Of Pay-For-Delay? FTC Sees An Opportunity In AndroGel Lawsuit

Reverse payment settlements are a popular tactic for settling patent disputes between brand companies and their generic competitors. The Federal Trade Commission has aggressively (but mostly unsuccessfully) fought “pay-for-delay” deals in the courts, arguing that they drive up drug prices. Now FTC has its best chance yet at convincing the Supreme Court to hear the issue. Is this the end of pay-for-delay?

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts